596 related articles for article (PubMed ID: 31424939)
1. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of
Gan Q; Song X; Zhang X; Zhang J
Eur J Med Chem; 2020 Feb; 188():112032. PubMed ID: 31926467
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.
Ramos N; Baquero-Buitrago J; Ben Youss Gironda Z; Wadghiri YZ; Reiner T; Boada FE; Carlucci G
J Nucl Med; 2020 Mar; 61(3):437-442. PubMed ID: 31481582
[TBL] [Abstract][Full Text] [Related]
4. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
5. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
6. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
7. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
9. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [
Elmi A; Makvandi M; Weng CC; Hou C; Clark AS; Mach RH; Mankoff DA
Clin Cancer Res; 2019 May; 25(10):3063-3073. PubMed ID: 30692100
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.
Shan H; Ma X; Yan G; Luo M; Zhong X; Lan S; Yang J; Liu Y; Pu C; Tong Y; Li R
Eur J Med Chem; 2021 Jul; 219():113432. PubMed ID: 33857728
[TBL] [Abstract][Full Text] [Related]
11. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
13. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
14. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
15. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
16. Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Nomanbhoy TK; Sharma G; Brown H; Wu J; Aban A; Vogeti S; Alemayehu S; Sykes M; Rosenblum JS; Kozarich JW
Biochemistry; 2016 Sep; 55(38):5434-41. PubMed ID: 27571378
[TBL] [Abstract][Full Text] [Related]
17. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
Paternot S; Colleoni B; Bisteau X; Roger PP
Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
[TBL] [Abstract][Full Text] [Related]
18. Preparation and Evaluation of [
Xiao D; Gan Q; Duan X; Wang Q; Jiang Y; Han P; Zhang J
Mol Pharm; 2023 Sep; 20(9):4528-4536. PubMed ID: 37661815
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
[TBL] [Abstract][Full Text] [Related]
20. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
